Summit Therapeutics Balance Sheet
NASDAQ: SMMTHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Summit Therapeutics financial position
At the end of fiscal 2025, Summit Therapeutics reported total assets of $751.2 million, up 72.5% from a year earlier against total liabilities of $92.3 million. Shareholders' equity stood at $658.9 million, or 87.7% of assets. The company held $225.3 million in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 9.87, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
Summit Therapeutics balance sheet (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-01-31 |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 225.27M | 104.86M | 71.42M | 348.61M | 71.79M | 66.42M | 35.24M |
| Short-Term Investments | 488.18M | 307.49M | 114.82M | 0 | — | — | — |
| Receivables | — | — | 0 | 349.00K | 1.46M | 331.00K | — |
| Total Current Assets | 720.30M | 423.75M | 189.71M | 656.71M | 97.31M | 87.67M | — |
| Property, Plant & Equipment | 1.06M | 254.00K | 204.00K | 906.00K | 694.00K | 725.00K | — |
| Goodwill | 2.00M | 1.86M | 1.89M | 1.80M | 2.01M | 2.03M | 1.95M |
| Intangible Assets | — | 0 | 0 | 0 | 10.40M | 11.52M | — |
| Total Assets | 751.18M | 435.56M | 202.95M | 664.17M | 113.37M | 102.50M | — |
| Accounts Payable | 20.29M | 4.64M | 2.67M | 355.00K | 4.37M | 6.14M | — |
| Total Current Liabilities | 72.99M | 41.73M | 20.41M | 38.78M | 25.62M | 19.89M | — |
| Long-Term Debt | — | 0 | 100.00M | 494.54M | — | — | — |
| Total Liabilities | 92.32M | 46.81M | 125.26M | 537.51M | 30.09M | 23.05M | — |
| Shareholders' Equity | 658.86M | 388.75M | 77.69M | 126.65M | 83.28M | 79.45M | 57.59M |
| Retained Earnings | -2.29B | -1.21B | -993.26M | -378.33M | -299.55M | -210.95M | — |
| Total Debt | — | 0 | 100.00M | 494.54M | — | — | — |
| Net Cash (Debt) | 713.45M | 412.35M | 86.24M | -145.93M | 71.79M | 66.42M | 35.24M |
| Shares Outstanding | 775.37M | 737.63M | 701.66M | 211.09M | 98.04M | 82.58M | — |
This table shows 7 annual periods of Summit Therapeutics's balance sheet, from FY 2025 back to FY 2019, across 17 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow SMMT's reporting calendar. What is a balance sheet?